Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 8/20 | 0.43 |
| ▸ | CASP3 | P42574 | 5/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535805 | 1.00 | GABRA5 (0.43) | GABRA5CASP3SENP8SENP7SENP6 | |
| SCHEMBL535835 | 0.83 | GABRA5 (0.42) | GABRA5NPC1RAB9AL3MBTL1TP53 | |
| SCHEMBL535834 | 0.83 | GABRA5 (0.42) | GABRA5NPC1RAB9AL3MBTL1TP53 | |
| SCHEMBL286527 | 0.83 | CASP3 (0.48) | GABRA5CASP3SENP8SENP7SENP6 | |
| SCHEMBL286528 | 0.83 | CASP3 (0.48) | GABRA5CASP3SENP8SENP7SENP6 | |
| SCHEMBL535861 | 0.81 | GABRA5 (0.43) | GABRA5CASP3SENP8SENP7SENP6 | |
| SCHEMBL535860 | 0.81 | GABRA5 (0.43) | GABRA5CASP3SENP8SENP7SENP6 | |
| SCHEMBL535762 | 0.79 | GABRA5 (0.72) | GABRA5 | |
| SCHEMBL535763 | 0.79 | GABRA5 (0.72) | GABRA5 | |
| SCHEMBL535808 | 0.78 | RAB9A (0.42) | GABRA5CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414354-B1 | Hydroxy-methyl isoxazole derivatives as gaba a modulators | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-8222246-B2 | Substituted isoxazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2414354-A1 | Hydroxy-methyl isoxazole derivatives as gaba a modulators | F. Hoffmann-La Roche AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112475-A1 | HYDROXY-METHYL ISOXAZOLE DERIVATIVES AS GABA A MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256127-A1 | SUBSTITUTED ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256127-A1 | SUBSTITUTED ISOXAZOLES | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885CASP3 3536/4885SENP8 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.